Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Matridex Dermal Filler presentationm to FACE Conference 2005 by Dr. Patrick Treacy

3,238 views

Published on

Presentation to F.A.C.E. Conference in 2005 by Dr. Patrick Treacy about Matridex Dermal Filler

Published in: Technology, Health & Medicine
  • Fioricet is often prescribed for tension headaches caused by contractions of the muscles in the neck and shoulder area. Buy now from http://www.fioricetsupply.com and make a deal for you.
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here

Matridex Dermal Filler presentationm to FACE Conference 2005 by Dr. Patrick Treacy

  1. 1. Matrix Engineering A New Concept of Treatment for Skin Rejuvenation Dr Patrick J. Treacy Ailesbury Clinic Dublin
  2. 2. MEDICAL DISCLOSURE: <ul><li>Dr. Patrick J. Treacy is a Cosmetic Doctor registered in UK and Ireland </li></ul><ul><li>I have previously been registered in United States, Australia, New Zealand and South Africa. </li></ul><ul><li>I have no financial interest or stock in BIoPolymer GmbH & Co KG </li></ul><ul><li>I receive no additional remuneration for stock bought by you after attendance at this lecture . </li></ul>
  3. 3.
  4. 4. Matrix Engineering <ul><li>Any new tissue formation such as collagenesis in the dermal compartment of the skin is dependant on many different factors: </li></ul><ul><li>Cells, Cytokines and Extra Cellular Matrix (ECM ). </li></ul><ul><li>The verification of new collagen after a special treatment is demonstrated by High Frequency Echo Sounder as a non-invasive instrument for clinical research. </li></ul>
  5. 5. Cells Cytokines Molecular Dermal Biology Extra Cellular Matrix ( ECM )
  6. 6. Methods and Systematics of Dermal Matrix Engineering Stimulation Collagenesis Microbeads New tissue formation Collagen type I Substitution of Hyaluronic acid
  7. 7. Treatment INTRADERMAL Wrinkles, folds, lip augmentation, lip contour, glabella, naso-labial, fine lines You can use the same product only changing the needle! 22
  8. 8. Matrix Engineering = Augmentation + Regeneration <ul><li>Immediate excellent augmentation of wrinkles and folds </li></ul><ul><li>because of the HylanGel Copolymer </li></ul><ul><li>(RHAI technique). </li></ul><ul><li>Evidence that the positively charged microbeads leads to the creation of new collagen and for a regeneration of the dermis. </li></ul>
  9. 9. The RHAI – technique  <ul><li>By cross-linking sodium hyaluronate a R eticulated H yaluronic A cid I mplant ( RHAI ) is designed. </li></ul><ul><li>In combination with naturally hyaluronic acid and hypromellose a viscoelastic co-polymer is created for biomedical matrix engineering. </li></ul>
  10. 10. Essentials required for the size and texture of particulate material <ul><li>Spherical microspheres or microbeads </li></ul><ul><li>Minimum diameter should be 40 µ </li></ul><ul><li>Smooth, homogeneous surface </li></ul><ul><li>Liquid biocompatible medium </li></ul>
  11. 11. Interaction of cells/tissue with microparticles <ul><li>Macrophage interaction with the biomaterial </li></ul><ul><li>Leads to acute and chronic inflammation </li></ul><ul><li>Results in formation of a fibrous capsule </li></ul><ul><li>Leads to new collagen formation </li></ul>
  12. 12. Interaction of cells/tissue with microparticles <ul><li>These effects are related to </li></ul><ul><li>Surface S mooth </li></ul><ul><li>Size 40 to 150 µm </li></ul><ul><li>Shape S pherical </li></ul><ul><li>Structure B iocompatible </li></ul><ul><li>Carrier L iquid medium </li></ul>
  13. 13. Different Shape and Surface structure of microparticles <ul><li>Irregular shape + </li></ul><ul><li>Rough surface structure </li></ul><ul><li>resulted in: </li></ul><ul><li>Foreign body reaction </li></ul><ul><li>Regular shape+ </li></ul><ul><li>Smooth surface </li></ul><ul><li>resulted in: </li></ul><ul><li>Fibrous tissue with </li></ul><ul><li>neocollagenesis </li></ul>
  14. 14. Migration of particles in the dermal compartment <ul><li>The critical particle size to avoid the phenomenon of migration is 80 to 120 µm </li></ul><ul><li>The extracellular migration caused by mechanical forces (muscle movement, gravity) is called dislocation </li></ul>
  15. 15. Types of Microparticles <ul><li>Permanent </li></ul><ul><li>Polymethylmethacrylate </li></ul><ul><li>Polyvinylhydroxid </li></ul><ul><li>Biodegradable </li></ul><ul><li>Dextranomere </li></ul><ul><li>Hylan Gel particle (xHA) </li></ul>
  16. 16. Matrix Engineering with Matridex <ul><li>Matridex is a new resorbable gel-suspension </li></ul><ul><li>for the treatment of skin defects (wrinkles).In comparison to all other fillers, it works with two effects: </li></ul><ul><li>Replacement of lost hayluronic acid ( augmentation ) </li></ul><ul><li>New formation of collagenous tissue </li></ul><ul><li>( regeneration ) </li></ul>
  17. 17. Composition <ul><li>1 ml Matridex contains: </li></ul><ul><li>Hyaluronic acid 25 mg </li></ul><ul><li>Hylan Gel 25 mg </li></ul><ul><li>Hypromellos 15 mg </li></ul><ul><li>DEAE Sephadex 25 mg </li></ul><ul><li>CE 1275 </li></ul>
  18. 18. Hylan Gel <ul><li>Crosslinked hyaluronic acid </li></ul><ul><li>Biocompatible </li></ul><ul><li>Non-tissue reactive </li></ul><ul><li>Non-antigenic </li></ul><ul><li>High hydration level </li></ul><ul><li>Water insoluble </li></ul><ul><li>Hyaluron, its Crosslinked Derivates – Hylan – and their Medical Application, </li></ul><ul><li>Balazs, Leshchiner, 1989 </li></ul><ul><li>Hylan Gel Biomaterial: Dermal and immunologic compatibility, </li></ul><ul><li>Larsen,Pollack,Balazs, 1993 </li></ul><ul><li>In vitro Cytotoxicity Report </li></ul><ul><li>BioService Project No. 021863, </li></ul><ul><li>2002 </li></ul>
  19. 19. Hypromellose Gel <ul><li>Hydroxypropylmethyl-cellulose (HPMC) </li></ul><ul><li>Biocompatible </li></ul><ul><li>Viscoelastic </li></ul><ul><li>Non-inflammatory </li></ul><ul><li>Chemical and physical properties of Methocel(HPMC) and ist clinical use </li></ul><ul><li>Kamman, 1997 </li></ul><ul><li>Studies of Irritating Action of Methylcellulose </li></ul><ul><li>Fleming, 1959 </li></ul>
  20. 20. Dextranomere <ul><li>Crosslinked Dextran </li></ul><ul><li>Beads </li></ul><ul><li>Spherical </li></ul><ul><li>Size from 80µ - 125µ </li></ul><ul><li>Charged surfaces </li></ul><ul><li>- positively (Matridex/DEAE Sephadex) </li></ul><ul><li>- negatively </li></ul><ul><li>Regulatory support file Sephadex, </li></ul><ul><li>Pharmacia, 2002 </li></ul><ul><li>Regulatory support file DEAE Sephadex, Pharmacia, 2002 </li></ul><ul><li>Regulatory support file CM Sephadex, Pharmacia, 2002 </li></ul>
  21. 21. Dextranomere Tradename: Sephadex <ul><li>Neutral, uncharged beads 40-60 µ leads to migration and granuloma formation </li></ul><ul><li>Negatively charged CM beads stimulating osteogenesis, new bone formation </li></ul><ul><li>Positively charged DEAE beads 80-125 µ no migration, stimulation of collagenesis </li></ul><ul><li>Heel,R.C.,Morton,P.,Brogden,R.N.: „Dextranomere. A review of ist general properties and therapeutic efficacy.“ </li></ul><ul><li>Drugs 1979;18:89-102 </li></ul>
  22. 22. Biocompatibility <ul><li>Biocompatible </li></ul><ul><li>Biodegradable </li></ul><ul><li>Non-sensitization </li></ul><ul><li>Non-cytotoxicity </li></ul><ul><li>Biocompatible viscoelastic gel slurries, their preparation and use </li></ul><ul><li>Leshchiner, 1991 </li></ul><ul><li>Implantation study of Matridex </li></ul><ul><li>Histology report </li></ul><ul><li>ISO 10993-6, 2002 </li></ul><ul><li>Cytotoxicity Assay Matridex </li></ul><ul><li>ISO 10993-5, 2002 </li></ul><ul><li>Sensitization Assay Matridex </li></ul><ul><li>ISO 10993-10, 2002 </li></ul>
  23. 23. Performance <ul><li>Transfer of collagen-stimulating substances </li></ul><ul><li>Transfer of skin hydrating substances </li></ul><ul><li>Transfer of skin regenerating substances </li></ul><ul><li>Enhanced Healing of cutaneous wounds using beads with positively charged surfaces </li></ul><ul><li>Mustoe, 1992 </li></ul><ul><li>Comparative rheological behavior of Hyaluronan from bacterial and animal sources with crosslinked Hyaluronan (Hylan Gel) in aqueous solution </li></ul><ul><li>Milas, 2001 </li></ul><ul><li>Biocompatible visvoelastic slurries, their preparation and use </li></ul><ul><li>Larsen, 1991 </li></ul><ul><li>Implantation Assay Matridex BioService Report No. 021627, 2002 </li></ul>
  24. 24. Startseite INDICATIONS AND INSTRUCTIONS FOR USE
  25. 26. Injecting technique: When using Matridex or Matridur it is recommanded only injecting in the vermillion border zone. Not from the inner site of the lips ( vestibulum ).
  26. 27. Histology Report 3/52 <ul><li>INTERMATERIAL SPACE </li></ul><ul><li>Small collagen fibre bundles (1 to 10 µm in width) </li></ul><ul><li>Capillaries and fibroblasts </li></ul><ul><li>Macrophages are in close apposition to the beads. </li></ul><ul><li>Sirius red and blue, OM 100 x </li></ul>
  27. 28. Histology Report 1year <ul><li>Extensive fibroblast and collagen exist in the intermaterial space </li></ul><ul><li>Absence of neutrophilic or lymphocytic infiltrate. </li></ul><ul><li>Hematoxylin and eosin, OM 40 x </li></ul><ul><li>Fig. 3 </li></ul>
  28. 29. 1 year after Implantation
  29. 30. No Skin Test Required <ul><li>Non-animal origin of the raw materials in Matridex and Matridur (ex fermentation). </li></ul><ul><li>The basic hyaluronic acid (HA) contains only 0.025 I.U./mg of Endotoxins. </li></ul><ul><li>Highest purity for Hyaluronic acid (HA) </li></ul>
  30. 33. Verification of New Collagen after Treatment High Frequency Echo Sounder Collagenoson DLX MATRIDEX
  31. 34. VERIFICATION OF NEOCOLLAGENESIS Face-Measurements with the Minhorst- Collagenoson before/after Matridex implantation 1 Minute after implantation 3 weeks after implantation NEW COLLAGEN 18 months after implantation NEW COLLAGEN REMAINS
  32. 35. Implantation Implantation <ul><li>intradermal </li></ul><ul><li>bevel of the needle up </li></ul><ul><li>slight molding after implantation </li></ul><ul><li>repetition after 3 weeks is recommanded ( cumulative effect of the stimulation ) </li></ul>
  33. 36. 1 year after Implantation
  34. 37. BioPolymer GmbH & Co.KG Germany E-mail [email_address]

×